Who is sponsoring NCT03859752?

NCT03859752 is sponsored by Open Innovation Partners, Inc..

What drugs are being tested in NCT03859752?

Interventions in NCT03859752: TR1801-ADC.

What condition does NCT03859752 study?

NCT03859752 studies Unspecified Adult Solid Tumor, Protocol Specific.

Is NCT03859752 still recruiting?

NCT03859752 is currently suspended. Last updated 22 September 2023.

Last reviewed 2023-09-22 · How we verify

NCT03859752

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TR1801-ADC in Patients With Tumors That Express c-Met

Suspended Phase 1 Last updated 22 September 2023

What this trial tests

Phase 1 trial testing TR1801-ADC in Unspecified Adult Solid Tumor, Protocol Specific in 15 participants. Suspended.

Timeline

14 August 2019

Primary endpoint
4 July 2023

31 December 2023

Quick facts

Lead sponsor	Open Innovation Partners, Inc.
Phase	Phase 1
Status	Suspended
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	14 August 2019
Primary completion	4 July 2023
Estimated completion	31 December 2023
Sites	4 locations across United States

Drugs / interventions tested

TR1801-ADC — full drug profile →

Conditions studied

Unspecified Adult Solid Tumor, Protocol Specific — all drugs for Unspecified Adult Solid Tumor, Protocol Specific →

Sponsor

Open Innovation Partners, Inc. — full company profile →

Who can join

18 and older, any sex, with Unspecified Adult Solid Tumor, Protocol Specific. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

First-in-human, Phase 1 study to assess safety, tolerability, and pharmacokinetics of TR1801-ADC in patients with select solid tumors that express c-Met.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.
Cooper AJ, Sequist LV, Lin JJ. · · 2022 · cited 382× · PMID 35534623 · DOI 10.1038/s41571-022-00639-9
Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U, Parakh S, Gan HK, Scott AM. · · 2020 · cited 283× · PMID 33081383 · DOI 10.3390/molecules25204764
Antibody-drug conjugates in solid tumors: a look into novel targets.
Criscitiello C, Morganti S, Curigliano G. · · 2021 · cited 169× · PMID 33509252 · DOI 10.1186/s13045-021-01035-z
Targeting cancer with antibody-drug conjugates: Promises and challenges.
Dean AQ, Luo S, Twomey JD, Zhang B. · · 2021 · cited 145× · PMID 34291723 · DOI 10.1080/19420862.2021.1951427
Resistance to antibody-drug conjugates: A review.
Li S, Zhao X, Fu K, Zhu S, et al · · 2025 · cited 32× · PMID 40177568 · DOI 10.1016/j.apsb.2024.12.036
Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies.
Ou X, Gao G, Habaz IA, Wang Y. · · 2024 · cited 30× · PMID 39184861 · DOI 10.1002/mco2.694
Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC).
Deneka AY, Boumber Y, Beck T, Golemis EA. · · 2019 · cited 21× · PMID 31484422 · DOI 10.3390/cancers11091297
Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review.
Perrotti V, Caponio VCA, Mascitti M, Lo Muzio L, et al · · 2021 · cited 18× · PMID 34206707 · DOI 10.3390/cancers13133126

Verify or expand the search:

Other recruiting trials for Unspecified Adult Solid Tumor, Protocol Specific

Currently open trials in the same condition.

NCT02112565 — RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Stand · Phase 1 · active not recruiting
NCT02293954 — Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer · NA · active not recruiting
NCT00477958 — Assessment Tool for Older Patients With Cancer · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03859752 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Open Innovation Partners, Inc.
Last refreshed: 22 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03859752.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing